New Directions in the Management of Relapsed/Refractory Follicular Lymphoma: A Visiting Professor Lecture Series for Hematology/Oncology Fellows - Grosse Pointe Woods, MI

Friday, February 7, 2020, 12:00 PM - 1:00 PM, Van Elslander Cancer Center, 19229 Mack Avenue

AMA PRA Category 1 Credits™ (1.00 hours), AMA PRA Category 1 Credits™ Designated (1.00 hours)

Of the estimated 74,200 new cases of non-Hodgkin lymphoma each year in the United States, approximately 22% are follicular lymphoma (FL), an indolent, diffcult-to-treat B-cell malignancy. Most patients are diagnosed at an average age of 63 years. Despite the introduction of novel therapies during the past decade, complications such as delayed presentation and treatment and evolving disease subtypes continue to hamper patient outcomes, and multiple recurrences with available therapies are common. Currently, allogeneic hematopoietic stem cell transplant is the only curative therapeutic modality for relapsed/refractory disease. However, the risk for comorbidities and secondary cancers limits the utility of this treatment upfront. Further research is required to determine the optimal timing and role of transplant and novel therapies to keep the remission rate among FL patients high and durable.

There is no fee to participate in or claim CME credit for this activity.

In order to receive credit for this activity, participants must submit a completed evaluation at the end of the activity.

To request a meeting for your institution, complete the following Request a Meeting application - click here. For questions, please contact Madelyne Fabrizio, Program Coordinator, at [email protected] or 973-928-8085 ext 216.

1. Evaluate patient and disease-related factors that can inform personalized care plans for patients with relapsed/refractory FL;
2. Assess emerging efficacy and safety data on novel therapeutic approaches for relapsed/refractory FL;
3. Outline strategies to integrate novel therapies into current FL clinical practice.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati and i3 Health Medical Education. The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.

The University of Cincinnati designates this enduring material activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credits commensurate with the extent of their participation in the activity.

Disclosures / Conflict of Interest Policy

In accordance with ACCME requirements, the University of Cincinnati College of Medicine has a conflict of interest policy that requires, all faculty, planning committee members, and other individuals who are in a position to control content, to disclose any relevant relationships with any commercial interest related to this activity. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation. All educational materials are reviewed for fair balance, scientific objectivity and levels of evidence. Disclosure will be made at the time of activity.

University of Cincinnati staff members, i3 Health staff members, and the peer/content reviewers for this activity have no relevant financial relationships to disclose.

Medical Director & Program Planners

i3Health Education

Anas Younes, MD, Course Director
Michael Bramwell, MPH
Sandra Ruesch, MSN, RN, CEN, CPEN, SANE-A
Amanda Thompson, Managing Editor

University of Cincinnati Continuing Medical Education Office

Bruce Gebhardt, MD
Susan P. Tyler, MEd, CMP, CHCP, Director
Heather Muskopf, Program Manager

Unapproved Use Disclosure
The University of Cincinnati and i3 Health require CME faculty (speakers) to disclose to attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved), as well as any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty may discuss information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.

Disclaimer Statement
The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic, and treatment options of a specific patient’s medical condition.

This educational activity is supported by independent educational grants from Bayer Healthcare Pharmaceuticals and Celgene Corporation.